Mostrar el registro sencillo del ítem
Proactive monitoring of anti-TNF agents improves follow-up of paediatric patients with Crohn disease
dc.contributor.author | Martin‐Masot, Rafael | |
dc.contributor.author | Rodríguez Azor, Begoña | |
dc.contributor.author | Dayaldasani Khialani, Anita | |
dc.contributor.author | Fernández Martín, Jesús María | |
dc.contributor.author | Gallego Fernández, Carmen | |
dc.contributor.author | Navas-López, Víctor Manuel | |
dc.date.accessioned | 2024-09-30T09:03:57Z | |
dc.date.available | 2024-09-30T09:03:57Z | |
dc.date.issued | 2023 | |
dc.identifier.citation | Rodríguez Azor B, Martín-Masot R, Dayaldasani Khialani A, Fernández-Martín JM, Gallego Fernández C, Navas-López VM. Proactive monitoring of anti-TNF agents improves follow-up of paediatric patients with Crohn disease. An Pediatr (Engl Ed). 2023 Mar;98(3):165-174. | es_ES |
dc.identifier.uri | https://hdl.handle.net/10630/33970 | |
dc.description.abstract | Introduction and aims: The incidence of paediatric inflammatory bowel disease has increased in recent decades. The aim of the present study was to evaluate the role of proactive and serial monitoring of tumour necrosis factor (TNF) inhibitor levels to maintain clinical remission and mucosal healing in the follow-up of paediatric patients with Crohn disease (CD). Methods: Prospective study that included all patients diagnosed with CD and treated with adalimumab or infliximab between May 2015 and November 2020 who underwent serial and proactive monitoring of TNF inhibitor levels. Results: The study included 30 patients, 21 male (70%). The mean age at diagnosis was 11.3 years (SD, 2.0), the mean age at initiation of TNF inhibitors was 12.6 years (SD, 1.9) with a mean duration of follow-up of 27.1 ± 9.1 months. Clinical remission was defined as a weighted Pediatric Crohn's Disease Activity Index (wPCDAI) of less than 12.5 and mucosal healing as a Mucosal Inflammation Non-invasive Index (MINI) of less than 8. During the follow-up, patients were in clinical remission in 87.1% of the visits, presented with mild disease in 11.4% and with moderate disease in 1.5%, and mucosal healing was assumed in 83% of the visits. The rates of clinical remission and mucosal healing at 1, 2, and 3 years of follow-up were 83.3%, 95.8%, 92.8%, and 86.7%, 87.5% and 85.7%, respectively. Conclusions: Proactive and serial monitoring of serum TNF inhibitor levels may make it possible for patients to maintain clinical remission and mucosal healing in the maintenance phase, with individualised optimization of the required dosage and minimization of secondary loss of response. | es_ES |
dc.language.iso | spa | es_ES |
dc.publisher | Elsevier | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | Intestinos - Inflamación | es_ES |
dc.subject.other | Inflammatory bowel disease | es_ES |
dc.subject.other | Therapeutic drug monitoring | es_ES |
dc.subject.other | Paediatric Crohn disease | es_ES |
dc.subject.other | Infliximab | es_ES |
dc.title | Proactive monitoring of anti-TNF agents improves follow-up of paediatric patients with Crohn disease | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.identifier.doi | 10.1016/j.anpede.2023.01.007 | |
dc.rights.cc | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.type.hasVersion | info:eu-repo/semantics/publishedVersion | es_ES |